Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Psychedelic Groundbreakers

26 Aug 2021

Psychedelic Groundbreakers: Ketamine Clinics Los Angeles

This week's Psychedelic Groundbreaker is Ketamine Clinics Los Angeles, a world-renowned provider of Ketamine Infusion Therapy....

By Microdose

Psychedelic Titans

24 Aug 2021

Psychedelic Titans with Justin Hanka of MindBio Therapeutics

This week's Psychedelic Titan is Justin Hanka of MindBio Therapeutics, pioneering clinical research into the microdosing of psychedelic medicines....

By Microdose

Psychedelic Groundbreakers

19 Aug 2021

Psychedelic Groundbreakers: MindBio Therapeutics

MindBio Therapeutics is a clinical-stage drug development company conducting research into microdosing & the medicinal use of psychedelic medicines....

By Microdose

Psychedelic Titans

17 Aug 2021

Psychedelic Titans with Christopher Moreau of Algernon Pharmaceuticals

This week's Psychedelic Titan is Christopher Moreau, CEO for Algernon Pharmaceuticals, a clinical-stage drug development company....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Psychedelic Titans

10 Aug 2021

Psychedelic Titans with Ben Sessa of Awakn Life Sciences

This week's Psychedelic Guide is Ben Sessa, Chief Medical Officer & Consultant Psychiatrist for Awakn Life Sciences...

By Microdose

Industry

4 Aug 2021

Executive Spotlight: Robin Arnott, Founder & CEO of Entheo Digital

Robin Arnott is the CEO of Entheo Digital, a digital therapeutics company developing and distributing experiences to support psychedelic therapists at all stages of journey work....

By Microdose

Press Releases

4 Aug 2021

The Conscious Fund and Departures Capital launch a Partnership to increase awareness for Public Companies within the Psychedelic Medicine Sector

The Conscious Fund and Departures Capital launch a Partnership to increase awareness for Public Companies within the Psychedelic Medicine Sector...

By Microdose

Psychedelic Titans

3 Aug 2021

Psychedelic Titans with Dr. Hyder A. Khoja of My Fungi Inc.

This week's Psychedelic Titan is Dr....

By Microdose

Psychedelic Groundbreakers

29 Jul 2021

Psychedelic Groundbreakers: Nasolution

This week's Psychedelic Groundbreaker is Nasolution, the first smart nasal solution for the safe self-administration of intranasal medication...

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.